Picture of Zhaoke Ophthalmology logo

6622 — Zhaoke Ophthalmology News Story

0.000.00%
hk flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Brief: Zhaoke Ophthalmology Says Positive Top-Line Data From Phase 3 Pivotal BRIO-I Trial Of Brimochol PF

April 25 (Reuters) - Zhaoke Ophthalmology Ltd  6622.HK :
    * POSITIVE TOP-LINE DATA FROM PHASE 3 PIVOTAL BRIO-I TRIAL
OF
BRIMOCHOL PF FOR TREATMENT OF PRESBYOPIA
    * PHASE 3 PIVOTAL BRIO-I TRIAL. BRIO-I MET PRE-SPECIFIED
PRIMARY
STUDY ENDPOINTS AGREED UPON WITH US-FDA AND EMA/MHRA

Source text for Eikon:  ID:nHKS7F9nH4 
Further company coverage:  6622.HK 

 ((reuters.briefs@thomsonreuters.com;))

Recent news on Zhaoke Ophthalmology

See all news